Interleukin-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial
- PMID: 38715466
- DOI: 10.1093/bjd/ljae186
Interleukin-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial
Conflict of interest statement
Conflicts of interest C.G. has received research grants from Novartis and GSK, and has been an advisor and/or received speakers’ honoraria from the following companies: Boehringer Ingelheim, Janssen-Cilag, GSK, Lilly, Novartis, Pfizer and AstraZeneca.
Comment on
-
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study.Br J Dermatol. 2024 Oct 17;191(5):680-690. doi: 10.1093/bjd/ljae181. Br J Dermatol. 2024. PMID: 38735684 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources